Home › Upcoming votes › Sunshine Biopharma Inc.
Prior-year votes at Sunshine Biopharma Inc. → 2023-2024 season, in the search
Read the proxy statement on EDGAR
Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.
Annual meeting held online: election of five directors, auditor ratification and an amendment to raise the equity incentive plan's share authorization.
“Board has approved, subject to stockholder approval, an amendment to the 2023 Plan to increase the number of shares authorized for issuance thereunder to 7,000,000 shares of common stock” Find it in the filing
“are currently no shares available for issuance under the 2023 Plan.” Find it in the filing
“The maximum number of shares of common stock that may be issued under the 2023 Plan was increased to 3,415 shares (as adjusted for reverse splits) at the Company's 2025 shareholders meeting held in December 2025. All of these shares were issued to one of the Company's directors in April (500 shares) and August (2,915 shares) 2026.” Find it in the filing
“All of the nominees, except Andre Sokhn, are currently directors of the Company. Dr. Andrew Keller, a current director of the Company, will not be up for reelection at the Meeting.” Find it in the filing
“Most recently, as Regional Head, Africa at Abbott, from January 2022 to December 2025, he led a business of more than $25 million.” Find it in the filing
“will remain as previously set at five directors. Therefore, the five directors receiving the most votes "for" will be elected.” Find it in the filing
“September 24, 2025, the Company dismissed Bush & Associates as its independent registered public accounting firm and retained M&K CPAS, PLLC ("M&K") as its independent auditor.” Find it in the filing
“will be held online on December 29, 2026, at 10:00 a.m., Eastern Time, to vote on the following matters:” Find it in the filing
“is independent under Nasdaq rules: Mr. Natan, Mr. Sokhn and Dr. Kiderchah.” Find it in the filing
Last year’s proxy statement, page 18: “each of the following nominees for director is independent under Nasdaq rules: Mr. Natan, Dr. Keller and Dr. Kiderchah.”
Ballot read from the proxy statement and checked. As listed in Sunshine Biopharma Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | Election of Directors Director election |
Board | For | 5 nominees; support 99.9% to 99.9% |
| 2 | Ratification of M&K CPAS, PLLC as Our Independent Registered Public Accounting Firm Auditor |
Board | For | 99.9% support |
| 3 | Amendment to 2023 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder to 7,000,000 | Board | For | — |
From Sunshine Biopharma Inc.’s Form 8-K, filed December 12, 2025, for the meeting held December 11, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: Dr. Steve N. Slilaty | 99.9% | — |
| Elect Director: Mr. Camille Sebaaly | 99.9% | Elected |
| Elect Director: Dr. Rabi Kiderchah | 99.9% | Elected |
| Elect Director: Mr. David Natan | 99.9% | Elected |
| Elect Director: Dr. Andrew Keller | 99.9% | Elected |
| (ii) Ratification of the board of directors' appointment of M&K CPAS, PLLC as the Company's independent registered public accounting firm fo | 99.9% | — |
| (iii) Approval of an amendment to the Company's 2023 Equity Incentive Plan to increase the number of shares of common stock authorized for i | 99.8% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.